Company Overview - Sipai Health Technology Co., Ltd. is a leading medical technology and health management company in China, headquartered in Guangzhou, Shanghai, and Beijing [2] - The company aims to lead the digital transformation of the healthcare industry in China, providing quality and accessible medical services [2] - Sipai operates three business lines: health insurance services, specialty pharmacy business, and physician research assistance [2] Financial Performance - As of December 31, 2024, Sipai Health reported total revenue of 4.565 billion yuan, a year-on-year decrease of 3.11% [1] - The company recorded a net profit attributable to shareholders of -324 million yuan, a year-on-year decrease of 26.57% [1] - The gross profit margin stood at 8.46%, with a debt-to-asset ratio of 46.96% [1] Stock Performance - On July 7, the stock price of Sipai Health closed at 5.19 HKD per share, an increase of 8.35% with a trading volume of 60.082 million shares and a turnover of 311 million HKD [1] - Over the past month, Sipai Health has seen a cumulative increase of 24.74%, but has a year-to-date decline of 12.11%, underperforming the Hang Seng Index by 19.22% [1] Industry Valuation - The average price-to-earnings (P/E) ratio for the pharmaceutical and biotechnology industry is 1.96 times, with a median of 6.18 times [1] - Sipai Health's P/E ratio is -10.28 times, ranking 123rd in the industry [1] - Comparatively, other companies in the industry have the following P/E ratios: Qianjing Pharmaceutical at 0.86 times, Kingsray Biotechnology at 1.43 times, Dongrui Pharmaceutical at 3.06 times, and Jilin Changlong Pharmaceutical at 6 times [1]
思派健康（00314.HK）7月7日收盘上涨8.35%，成交3.11亿港元